Lobbying client · LD-2 disclosures
Regenxbio Inc.
Maryland
7 filings from 2 registrants · 2025–2026 · latest filed Jul 17, 2026
Reported on its behalf
$400K
every LD-2 on file
Its own filed spend
$0
lobbying for itself
Fees to outside firms
$400K
across every firm on file
Spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
What they lobby on
Issue areas declared on the filings, ranked by how many filings name each one.
Health Issues
HCR
5 filings
$280K on those filings
Pharmacy
PHA
4 filings
$240K on those filings
Medical/Disease Research/Clinical Labs
MED
Who did the lobbying
Every lobbyist named on this client's filings.
- Alanna Temme Lmh Strategic SolutionsCovered position: Legislative Director, U.S. Representative Jon Porter5 filingsthrough 2026
- Margaret Martin Dla Piper LLP (US)Covered position: Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard Burr4 filingsthrough 2026
- Karina Lynch Dla Piper LLP (US)4 filingsthrough 2026
- Richard Burr Dla Piper LLP (US)Covered position: U.S. Senator4 filings
The filings
Every filing on record. Each row links to its full disclosure.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: regenxbio-inc.